Cilostazol Has Beneficial Effects in Treatment of Intermittent Claudication Results From a Multicenter, Randomized, Prospective, Double-blind Trial
Reads0
Chats0
TLDR
In this paper, the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication was evaluated in a prospective, randomized, placebo-controlled, parallel-group clinical trial.Abstract:
Background—Cilostazol is a new phosphodiesterase inhibitor that suppresses platelet aggregation and also acts as a direct arterial vasodilator. This prospective, randomized, placebo-controlled, parallel-group clinical trial evaluated the efficacy of cilostazol for treatment of stable, moderately severe intermittent claudication. Methods and Results—Study inclusion criteria included age ≥40 years, initial claudication distance (ICD) on treadmill (12.5% incline, 3.2 km/h) between 30 and 200 m, and confirmation of diagnosis of chronic lower-extremity arterial occlusive disease. After stabilization and single-blind placebo lead-in, 81 subjects (62 male, 19 female) from 3 centers were randomized unequally (2:1) to 12 weeks of treatment with cilostazol 100 mg PO BID or placebo. Primary outcome measures included ICD and maximum distance walked (absolute claudication distance, or ACD). Secondary outcome measures included ankle pressures, subjective assessments of benefit by patients and physicians, and safety. Tr...read more
Citations
More filters
Journal ArticleDOI
ACC/AHA 2005 Practice Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic)
Alan T. Hirsch,Ziv J. Haskal,Norman R. Hertzer,Curtis W. Bakal,Mark A. Creager,Jonathan L. Halperin,Loren F. Hiratzka,William R.C. Murphy,Jeffrey W. Olin,Jules B. Puschett,Kenneth Rosenfield,David B. Sacks,James C. Stanley,Lloyd M. Taylor,Christopher J. White,John White,Rodney A. White,Elliott M. Antman,Sidney C. Smith,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,Raymond J. Gibbons,Sharon A. Hunt,Alice K. Jacobs,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +29 more
TL;DR: Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) A Collaborative Report from the American Association for Vascular Surgery/Society for V vascular surgery,* Society for Cardiovascular Angiography and Interventions, Society forVascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines.
Journal ArticleDOI
Diabetes and atherosclerosis: epidemiology, pathophysiology, and management.
TL;DR: Since most patients with diabetes die from complications of atherosclerosis, they should receive intensive preventive interventions proven to reduce their cardiovascular risk.
Journal ArticleDOI
Medical Treatment of Peripheral Arterial Disease and Claudication
TL;DR: Patients with peripheral arterial disease, even in the absence of a history of myocardial infarction or ischemic stroke, have approximately the same relative risk of death from cardiovascular causes as do patients with ahistory of coronary or cerebrovascular disease.
Journal ArticleDOI
ACC/AHA 2005 guidelines for the management of patients with peripheral arterial disease (Lower extremity, renal, mesenteric, and abdominal aortic): Executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vas
Alan T. Hirsch,Ziv J. Haskal,Norman R. Hertzer,Curtis W. Bakal,Mark A. Creager,Jonathan L. Halperin,Loren F. Hiratzka,William R.C. Murphy,Jeffrey W. Olin,Jules B. Puschett,Kenneth Rosenfield,David B. Sacks,James C. Stanley,Lloyd M. Taylor,Christopher J. White,John White,Rodney A. White,Elliot M Antman,Sidney C. Smith,Cynthia D. Adams,Jeffrey L. Anderson,David P. Faxon,Valentin Fuster,R. J. Gibbons,Sharon A. Hunt,Alice K. Jacobs,Rick A. Nishimura,Joseph P. Ornato,Richard L. Page,Barbara Riegel +29 more
TL;DR: The ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic) are published.
Journal ArticleDOI
Diabetes-Related Microvascular and Macrovascular Diseases in the Physical Therapy Setting
TL;DR: It is becoming increasingly important to be aware of diabetes-related vascular complications as more patients present with insulin resistance and diabetes, and the opportunities for effective physical therapy interventions (such as exercise) are significant.
References
More filters
Journal ArticleDOI
Suggested standards for reports dealing with lower extremity ischemia
Robert B. Rutherford,D.Preston Flanigan,Sushil K. Gupta,K. Wayne Johnston,Allastair M. Karmody,Anthony D. Whittemore,J.Dennis Baker,Calvin B. Ernst,Crawford Jamieson,Shanti Mehta +9 more
TL;DR: It is hoped that this committee's recommendations will help establish reporting standards for articles dealing with lower extremity ischemia, and certain terms are defined and criteria offered for uniformly gauging the severity of disease, the findings of diagnostic studies, the types of therapeutic interventions, and the outcome of such treatments.
Journal ArticleDOI
Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients.
John M. Porter,Bruce S. Cutler,Bok Y Lee,Theobald Reich,Frederick A Reichle,John T Scogin,D.Eugene Strandness +6 more
TL;DR: Pentoxifylline given orally in doses up to 1200 mg/day was significantly more effective than placebo in increasing both the initial and absolute claudication distances in patients with COAD.
Journal Article
Effect of cilostazol on platelet aggregation and experimental thrombosis.
TL;DR: The drug potently prevented death due to pulmonary thrombosis by platelet aggregates in mice in vivo and cilostazol is a promising antithrombotic drug.
Journal ArticleDOI
Effects of Cilostazol, a Selective cAMP Phosphodiesterase Inhibitor on the Contraction of Vascular Smooth Muscle
TL;DR: The effects of cilostazol (OPC-13013, 6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydro-2(1H)-quin olinone) on cyclic nucleotide metabolism and Ca2+-induced contraction of intact and skinned rabbit arterial smooth muscles were investigated as discussed by the authors.
Journal ArticleDOI
Effect of cilostazol, a cyclic AMP phosphodiesterase inhibitor, on the proliferation of rat aortic smooth muscle cells in culture.
Sadao Takahashi,Koji Oida,Ryuichi Fujiwara,Hajime Maeda,Shinta Hayashi,Hirotada Takai,Toshitaka Tamai,Tsuguhiko Nakai,Susumu Miyabo +8 more
TL;DR: It is suggested that cilostazol, by interfering with the proliferation of arterial SMCs, may have potential to prevent initiation and progression of atherosclerosis.